Characterization of sequence determinants of enhancer function using natural genetic variation

  1. Marty G Yang
  2. Emi Ling
  3. Christopher J Cowley
  4. Michael E Greenberg  Is a corresponding author
  5. Thomas Vierbuchen  Is a corresponding author
  1. Harvard University, United States
  2. Rockefeller University, Howard Hughes Medical Institute, United States
  3. Memorial Sloan Kettering Cancer Center, United States

Abstract

Sequence variation in enhancers that control cell type-specific gene transcription contributes significantly to phenotypic variation within human populations. However, it remains difficult to predict precisely the effect of any given sequence variant on enhancer function due to the complexity of DNA sequence motifs that determine transcription factor (TF) binding to enhancers in their native genomic context. Using F1-hybrid cells derived from crosses between distantly related inbred strains of mice, we identified thousands of enhancers with allele-specific TF binding and/or activity. We find that genetic variants located within the central region of enhancers are most likely to alter TF binding and enhancer activity. We observe that the AP-1 family of TFs (Fos/Jun) are frequently required for binding of TEAD TFs and for enhancer function. However, many sequence variants outside of core motifs for AP-1 and TEAD also impact enhancer function, including sequences flanking core TF motifs and AP-1 half sites. Taken together, these data represent one of the most comprehensive assessments of allele-specific TF binding and enhancer function to date and reveal how sequence changes at enhancers alter their function across evolutionary timescales.

Data availability

We submitted our data to GEO, and it is now accessible via GSE193728.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Marty G Yang

    Department of Neurobiology, Harvard University, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Emi Ling

    Department of Neurobiology, Harvard University, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5287-0284
  3. Christopher J Cowley

    Laboratory of Mammalian Cell Biology and Development, Rockefeller University, Howard Hughes Medical Institute, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Michael E Greenberg

    Department of Neurobiology, Harvard University, Boston, United States
    For correspondence
    meg@hms.harvard.edu
    Competing interests
    The authors declare that no competing interests exist.
  5. Thomas Vierbuchen

    Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, United States
    For correspondence
    vierbuct@mskcc.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5690-5680

Funding

NIH Office of the Director (T32EY00711030)

  • Marty G Yang

NIH Office of the Director (T32AG000222)

  • Marty G Yang

National Science Foundation (DGE0946799)

  • Emi Ling

National Science Foundation (DGE1144152)

  • Emi Ling

NIH Office of the Director (R01 NS115965)

  • Michael E Greenberg

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments were approved by the National Institutes of Health and the Harvard Medical School Institutional Animal Care and Use Committee and were conducted in compliance with the relevant ethical regulations (Protocol # IS00000074-3)

Copyright

© 2022, Yang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 509
    downloads

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Marty G Yang
  2. Emi Ling
  3. Christopher J Cowley
  4. Michael E Greenberg
  5. Thomas Vierbuchen
(2022)
Characterization of sequence determinants of enhancer function using natural genetic variation
eLife 11:e76500.
https://doi.org/10.7554/eLife.76500

Share this article

https://doi.org/10.7554/eLife.76500

Further reading

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Ananda Kishore Mukherjee, Subhajit Dutta ... Shantanu Chowdhury
    Research Article

    Telomeres are crucial for cancer progression. Immune signalling in the tumour microenvironment has been shown to be very important in cancer prognosis. However, the mechanisms by which telomeres might affect tumour immune response remain poorly understood. Here, we observed that interleukin-1 signalling is telomere-length dependent in cancer cells. Mechanistically, non-telomeric TRF2 (telomeric repeat binding factor 2) binding at the IL-1-receptor type-1 (IL1R1) promoter was found to be affected by telomere length. Enhanced TRF2 binding at the IL1R1 promoter in cells with short telomeres directly recruited the histone-acetyl-transferase (HAT) p300, and consequent H3K27 acetylation activated IL1R1. This altered NF-kappa B signalling and affected downstream cytokines like IL6, IL8, and TNF. Further, IL1R1 expression was telomere-sensitive in triple-negative breast cancer (TNBC) clinical samples. Infiltration of tumour-associated macrophages (TAM) was also sensitive to the length of tumour cell telomeres and highly correlated with IL1R1 expression. The use of both IL1 Receptor antagonist (IL1RA) and IL1R1 targeting ligands could abrogate M2 macrophage infiltration in TNBC tumour organoids. In summary, using TNBC cancer tissue (>90 patients), tumour-derived organoids, cancer cells, and xenograft tumours with either long or short telomeres, we uncovered a heretofore undeciphered function of telomeres in modulating IL1 signalling and tumour immunity.

    1. Cell Biology
    2. Chromosomes and Gene Expression
    Bethany M Bartlett, Yatendra Kumar ... Wendy A Bickmore
    Research Article Updated

    During oncogene-induced senescence there are striking changes in the organisation of heterochromatin in the nucleus. This is accompanied by activation of a pro-inflammatory gene expression programme – the senescence-associated secretory phenotype (SASP) – driven by transcription factors such as NF-κB. The relationship between heterochromatin re-organisation and the SASP has been unclear. Here, we show that TPR, a protein of the nuclear pore complex basket required for heterochromatin re-organisation during senescence, is also required for the very early activation of NF-κB signalling during the stress-response phase of oncogene-induced senescence. This is prior to activation of the SASP and occurs without affecting NF-κB nuclear import. We show that TPR is required for the activation of innate immune signalling at these early stages of senescence and we link this to the formation of heterochromatin-enriched cytoplasmic chromatin fragments thought to bleb off from the nuclear periphery. We show that HMGA1 is also required for cytoplasmic chromatin fragment formation. Together these data suggest that re-organisation of heterochromatin is involved in altered structural integrity of the nuclear periphery during senescence, and that this can lead to activation of cytoplasmic nucleic acid sensing, NF-κB signalling, and activation of the SASP.